Preview document (🔗 origineel)

---

Bijlage bij Kamervragen over medicinale cannabis

Literatuurlijst (1-84) uit:

Hazekamp A, Grotenhermen F. Review on clinical studies with cannabis and
cannabinoids 2005-2009. Cannabinoids 2010;5 (special issue):1-21

Abrams DI, Hilton JF, Leiser RJ, Shade SB, Elbeik TA, Aweeka FT,
Benowitz NL, Bredt BM, Kosel B, Aberg JA, Deeks SG, Mitchell TF,
Mulligan K, Bacchetti P, McCune JM, Schambelan M. Short-term effects of
cannabinoids in patients with HIV-1 infection: a randomized,
placebo-controlled clinical trial. Ann. Intern. Med.
2003;139(4):258-266.

Abrams DI, Jay CA, Shade SB, Vizoso H, Reda H, Press S, Kelly ME,
Rowbotham MC, Petersen KL. Cannabis in painful HIV-associated sensory
neuropathy: a randomized placebo-controlled trial. Neurology
2007;68(7):515-521.

Agurell S, Carlsson S, Lindgren JE, Ohlsson A, Gillespie H, Hollister L.
Interactions of delta 1- tetrahydrocannabinol with cannabinol and
cannabidiol following oral administration in man. Assay of cannabinol
and cannabidiol by mass fragmentography. Experientia
1981;37(10):1090-1092.

Aragona M, Onesti E, Tomassini V, Conte A, Gupta S, Gilio F, Pantano P,
Pozzilli C, Inghilleri M. Psychopathological and cognitive effects of
therapeutic cannabinoids in multiple sclerosis: a double-blind, placebo
controlled, crossover study. Clin. europharmacol. 2009;32(1):41-47.

Backonja M, Beydoun A, Edwards KR, Schwartz SL, Fonseca V, Hes M,
LaMoreaux L, Garofalo E. Gabapentin for the symptomatic treatment of
painful neuropathy in patients with diabetes mellitus: a randomized
controlled trial. JAMA 1998;280:1831-1836.

Bateman DN. Delta-9-tetrahydrocannabinol and gastric emptying. Br. J.
Clin. Pharmacol. 1983; 15:749-751.

Beal J, Flynn N. AIDS-associated anorexia. J. Physicians Assoc. AIDS
Care 1995;2(1):19-22.

Beaulieu P. Effects of nabilone, a synthetic cannabinoid, on
postoperative pain. Can. J. Anaesth. 2006;53(8):769-775.

Ben Amar M. Cannabinoids in medicine: A review of their therapeutic
potential. J. Ethnopharm. 2006;105:1-25.

Bisogno T, Hanus L, De Petrocellis L, Tchilibon  S, Ponde SDE, Brandi I,
Moriello AS, Davis JB, Mechoulam R, Di Marzo V. Molecular targets for
cannabidiol and its synthetic analogues: effect on vanilloid VR1
receptors and on the cellular uptake and enzymatic hydrolysis of
anandamide. Br. J. Pharmacol. 2001;134(4):845-52.

Blake DR, Robson P, Ho M, Jubb RW, McCabe CS. Preliminary assessment of
the efficacy, tolerability and safety of a cannabis-based medicine
(Sativex) in the treatment of pain caused by rheumatoid arthritis.
Rheumatology (Oxford) 2006;45(1):50-52.

Bornheim LM, and Grillo MP. Characterization of cytochrome P450 3A
inactivation by cannabidiol: possible involvement of
cannabidiolhydroxyquinone as a P450 inactivator. Chem. Res. Toxicol.
1998;11(10):1209-1216.

Bornheim LM, Kim KY, Li J, Perotti BY, Benet LZ. Effect of cannabidiol
pretreatment on the kinetics of tetrahydrocannabinol metabolites in
mouse brain. Drug Metab. Dispos. 1995;23(8): 825-831.

Brady CM, DasGupta R, Wiseman OJ, Dalton CM, Berkley KJ, Fowler CJ. The
effect of cannabis based medicinal extract on lower urinary tract
dysfunction in advanced multiple sclerosis: preliminary results. Journal
of Neurology, Neurosurgery and Psychiatry 2002;72:139 

Christie MJ, Mallet C. Endocannabinoids can open the pain gate. Sci.
Signal. 2009;2(88):pe57.

Collin C, Davies P, Mutiboko IK, Ratcliffe S; Sativex Spasticity in MS
Study Group. Randomized controlled trial of cannabis-based medicine in
spasticity caused by multiple sclerosis. Eur. J. Neurol.
2007;14(3):290-296.

Conte, A, Marini Bettolo C, Onesti E, Frasca V, Iacovelli E, Gilio F,
Giacomelli E, Gabriele M, Aragona M, Tomassini V, Pantano P, Pozzilli C,
Inghilleri M. Cannabinoid-induced effects on the nociceptive system: A
neurophysiological study in patients with secondary progressive multiple
sclerosis. European Journal of Pain 2009;13:472-477.

Corchero J, Manzanares J, Fuentes JA. Cannabinoid/opioid crosstalk in
the central nervous system. Crit. Rev. Neurobiol. 2004;16:159-172.

Costa B, Trovato AE, Comelli F, Giagnoni G, Colleoni M. The
non-psychoactive cannabis constituent cannabidiol is an orally effective
therapeutic agent in rat chronic inflammatory and neuropathic pain. Eur.
J. Pharmacol. 2007;556(1-3):75-83.

Coyne KS, Matza LS, Thompson CL. The responsiveness of the Overactive
Bladder Questionnaire (OAB-q). Qual. Life Res. 2005;14:849-855.

Craft RM. Sex differences in behavioral effects of cannabinoids. Life
Sci. 2005;77:2471-2478.

D'Souza DC, Abi-Saab WM, Madonick S, Forselius-Bielen K, Doersch A,
Braley G, Gueorguieva R, Cooper TB, Krystal JH.
Delta-9-tetrahydro-cannabinol effects in schizophrenia: implications for
cognition, psychosis, and addiction. Biol. Psychiatry
2005;57(6):594-608.

Ellis RJ, Toperoff W, Vaida F, van den Brande G, Gonzales J, Gouaux B,
Bentley H, Atkinson JH. Smoked Medicinal Cannabis for Neuropathic Pain
in HIV: A Randomized, Crossover Clinical Trial. Neuropsychopharmacology
2009;34(3): 672-680.

Esfandyari T, Camilleri M, Busciglio I, Burton D, Baxter K, Zinsmeister
AR. Effects of a cannabinoid receptor agonist on colonic motor and
sensory functions in humans: a randomized, placebocontrolled study. Am.
J. Physiol. Gastrointest.Liver Physiol. 2007;293(1):G137-G145.

Esfandyari T, Camilleri M, Ferber I, Burton D, Baxter K, Zinsmeister AR.
Effect of a cannabinoid agonist on gastrointestinal transit and
postprandial satiation in healthy human subjects: a randomized,
placebo-controlled study. Neurogastroenterol. Motil. 2006;18(9):831-838.

Farrar JT, Young JP, La Moreaux L, Werth JL, Poole RM. Clinical
importance of changes in chronic pain intensity measured on an 11-point
numerical pain rating scale. Pain 2000;94:149-158.

Frank B, Serpell MG, Hughes J, Matthews JN, Kapur D. Comparison of
analgesic effects and patient tolerability of nabilone and
dihydrocodeine for chronic neuropathic pain: randomised, crossover,
double blind study. BMJ 2008;336(7637):199-201.

Freeman RM, Adekanmi O, Waterfield MR, Waterfield AE, Wright D, Zajicek
J. The effect of cannabis on urge incontinence in patients withmultiple
sclerosis: a multicentre, randomised placebo-controlled trial
(CAMS-LUTS). Int. Urogynecol. J. Pelvic Floor Dysfunct.
2006;17(6):636-641.

Giuffrida A, Leweke FM, Gerth CW, Schreiber D, Koethe D, Faulhaber J,
Klosterkötter J, Piomelli D. Cerebrospinal anandamide levels are
elevated in acute schizophrenia and are inversely correlated with
psychotic symptoms. Neuropsychopharmacology 2004;29(11):2108-2114.

Goldstein I, Siroky MB, Sax DS, Krane RJ. Neurourologic abnormalities in
multiple-sclerosis. J. Urol. 1982;128(3):541-545.

Guy GW, Robson P. A phase 1, double blind, three way crossover study to
assess the pharmacokinetic profile of cannabis based medicinal extract
(CBME) administered sublingually in variant cannabinoid ratios in normal
healthy male volunteers. J. Cannabis Ther. 2003;3:121-152.

Guzmán M, Duarte MJ, Blázquez C, Ravina J, Rosa MC, Galve-Roperh I,
Sánchez C, Velasco G, González-Feria L. A pilot clinical study of
Delta9-tetrahydrocannabinol in patients with recurrent glioblastoma
multiforme. Br. J. Cancer 2006;95(2):197-203.

Guzmán M. Cannabinoids: potential anticancer agents. Nat. Rev. Cancer
2003;3:745–755.

Haney M, Gunderson EW, Rabkin J, Hart CL, Vosburg SK, Comer SD, Foltin
RW. Dronabinol and marijuana in HIV-positive marijuana smokers. Caloric
intake, mood, and sleep. J. Acquir. Immune Defic. Syndr.
2007;45(5):545-554.

Haney M, Rabkin J, Gunderson E, Foltin RW. Dronabinol and marijuana in
HIV(+) marijuana smokers: acute effects on caloric intake and mood.
Psychopharmacology (Berl) 2005;181(1): 170-178.

Hepler RS, Frank IR. Marihuana smoking and intraocular pressure. JAMA
1971;217(10):1392.

Holdcroft A, Maze M, Doré C, Tebbs S, Thompson S. A multicenter
dose-escalation study of the analgesic and adverse effects of an oral
cannabis extract (Cannador) for postoperative pain management.
Anesthesiology 2006;104(5):1040-1046.

Hunt CA, Jones RT, Herning RI, Bachman J. Evidence that cannabidiol does
not significantly alter the pharmacokinetics of tetrahydrocannabinol in
man. J. Pharmacokinet. Biopharm. 1981; 9(3):245-260.

Institute of Medicine, Marijuana and medicine: assessing the scientific
base. National Academy Press, Washington DC, MD. 1999.

Iversen L. Cannabis and the brain. Brain 2003;126:1252-1270.

Jaeger W, Benet LZ, Bornheim LM. Inhibition of cyclosporine and
tetrahydrocannabinol metabolism by cannabidiol in mouse and human
microsomes. Xenobiotica 1996;26(3):275-284.

Jager G, Kahn RS, Van Den Brink W, Van Ree JM, Ramsey NF. Long-term
effects of frequent cannabis use on working memory and attention: an
fMRI study. Psychopharmacol (Berl) 2006;185:358-368.

Jay WM, Green K. Multiple drop study of topically applied 1%
delta-9-tetrahydrocannabinol in human eyes. Arch Ophthalmol.
1983;101:591-593.

Katona S, Kaminski E, Sanders H, Zajicek J. Cannabinoid influence on
cytokine profile in multiple sclerosis. Clin. Exp. Immunol. 2005;
140(3):580-585.

Kavia R, De Ridder D, Sarantis N, Constantinescu C, Fowler. Randomised
controlled trial of cannabis based medicine (CBM, Sativex®) to treat
detrusor overactivity in multiple sclerosis. Neurourology and
Urodynamics 2006;25:166-166.

Kraft B, Frickey NA, Kaufmann RM, Reif M, Frey R, Gustorff B, Kress HG.
Lack of analgesia by oral standardized cannabis extract on acute
inflammatory pain and hyperalgesia in volunteers. Anesthesiology
2008;109(1):101-110.

Leweke FM, Koethe D, Gerth CW, Nolden BM, Schreiber D, Hänsel A, Neatby
MA, Juelicher A, Hellmich M, Klosterkötter J. Cannabidiol as an
antipsychotic. A double-blind, controlled clinical trial on cannabidiol
vs. amisulpride in acute schizophrenia. Abstract for oral sessions /
European Psychiatry 2007;22:S14.02.

Lynch MA, Clark AJ. Cannabis reduces opioid dose in the treatment of
chronic non-cancer pain. Journal of Pain and Symptom Management
2003;25:496-498.

Maldonado R, Valverde O. Participation of the opioid system in
cannabinoid-induced anticiception and emotional-like responses. European
Neuropsychopharmacology 2003;13:401-410.

Manara L, Croci T, Guagnini F, Rinaldi-Carmona M, Maffrand JP, Le Fur G,
Mukenge S, Ferla G. Functional assessment of neuronal cannabinoid
receptors in the muscular layers of human ileum and colon. Dig. Liver
Dis. 2002;34:262-269.

Mechoulam R, Hanus L. Cannabidiol: an overview of some chemical and
pharmacological aspects. Part I: chemical aspects. Chem. Phys.
Lipids2002;121(1-2):35-43.

Meiri E, Jhangiani H, Vredenburgh JJ, Barbato LM, Carter FJ, Yang HM,
Baranowski V. Efficacy of dronabinol alone and in combination with
ondansetron versus ondansetron alone for delayed chemotherapy-induced
nausea and vomiting. Curr. Med. Res. Opin. 2007;23(3):533-543.

Millan MJ. Descending control of pain. Prog. Neurobiol. 2002;66:355-474.

Narang S, Gibson D, Wasan AD, Ross EL, Michna E, Nedeljkovic SS, Jamison
RN. Efficacy of dronabinol as an adjuvant treatment for chronic pain
patients on opioid therapy. J. Pain 2008;9(3):254-264

Nurmikko TJ, Serpell MG, Hoggart B, Toomey PJ, Morlion BJ, Haines D.
Sativex successfully treats neuropathic pain characterised by allodynia:
a randomised, double-blind, placebo-controlled clinical trial. Pain
2007;133(1-3):210-220.

Petitet F, Jeantaud B, Reibaud M, Imperato A, Dubroeucq MC. Complex
pharmacology of natural cannabinoids: evidence for partial agonist
activity of Δ9-tetrahydrocannabinol and antagonist activity of
cannabidiol on rat brain cannabinoid receptors. Life Sci.
1998;63(1):PL1-6.

Pinsger M, Schimetta W, Volc D, Hiermann E, Riederer F, Pölz W.
[Benefits of an add-on treatment with the synthetic cannabinomimetic
nabilone on patients with chronic pain--a randomized controlled trial]
[Article in German]. Wien Klin. Wochenschr. 2006;118(11-12):327-335.

Plange N, Arend KO, Kaup M, Doehmen B, Adams H, Hendricks S, Cordes A,
Huth J, Sponsel WE, Remky A. Dronabinol and retinal hemodynamics in
humans. Am. J. Ophthalmol. 2007;143(1):173-174.

Redmond WJ, Goffaux P, Potvin S, Marchand S. Analgesic and
antihyperalgesic effects of nabilone on experimental heat pain. Curr.
Med. Res. Opin. 2008;24(4):1017-1024.

Roberts JD, Gennings C, Shih M. Synergistic affective analgesic
interaction between delta-9-tetrahydrocannabinol and morphine. Eur.
J.Pharmacol. 2006;530(1-2):54-58.

Rog DJ, Nurmikko TJ, Friede T, Young CA. Randomized, controlled trial of
cannabis-based medicine in central pain in multiple sclerosis. Neurology
2005;65(6):812-819.

Rog DJ, Nurmikko TJ, Young CA. Oromucosal
delta9-tetrahydrocannabinol/cannabidiol for neuropathic pain associated
with multiple sclerosis: an uncontrolled, open-label, 2-year extension
trial. Clin. Ther. 2007;29(9):2068-2079.

Russo E, Guy GW. A tale of two cannabinoids: the therapeutic rationale
for combining tetrahydrocannabinol and cannabidiol. 2006;Med. Hypotheses
66(2):234-46.

Sandrini G, Arrigo A, Bono G, Nappi G. The nociceptive flexion reflex as
a tool for exploring pain control systems in headache and other pain
syndromes. Cephalalgia 1993;13:21-27.

Seeling W, Kneer L, Büchele B, Gschwend JE, Maier L, Nett C, Simmet T,
Steffen P, Schneider M, Rockemann M. [Delta(9)-tetrahydrocannabinol and
the opioid receptor agonist piritramide do not act synergistically in
postoperative pain] [Article in German]. Anaesthesist.
2006;55(4):391-400.

Shakespeare DT, Boggild M, Young C. Antispasticity agents for multiple
sclerosis (Cochrane Review). In: The Cochrane Library, Issue 3. Oxford:
Update Software: 2003.

Siegling A, Hofmann HA, Denzer D, Mauler F, De Vry J. Cannabinoid CB(1)
receptor upregulation in a rat model of chronic neuropathic pain. Eur.
J. Pharmacol. 2001;415(1):R5-7.

Skrabek RQ, Galimova L, Ethans K, Perry D. Nabilone for the treatment of
pain in fibromyalgia. J. Pain 2008;9(2):164-173.

Smith FL, Cichewicz D, Martin ZL, Welch SP. The enhancement of morphine
antinociception in mice by delta9-tetrahydrocannabinol. Pharmacol.
Biochem. Behav. 1998;60:559-566.

Strasser F, Luftner D, Possinger K, Ernst G, Ruhstaller T, Meissner W,
Ko YD, Schnelle M, Reif M, Cerny T. Comparison of orally administered
cannabis extract and delta-9-tetrahydrocannabinol in treating patients
with cancer-related anorexia-cachexia syndrome: a multicenter, phase
III, randomized, double-blind, placebo-controlled clinical trial from
the Cannabis-In-Cachexia-Study-Group. J. Clin. Oncol.
2006;24(21):3394-3400.

Svendsen KB, Jensen TS, Bach FW. Does the cannabinoid dronabinol reduce
central pain in multiple sclerosis? Randomised double blind placebo
controlled crossover trial. BMJ 2004;329(7460):253.

Sylvestre DL, Clements BJ, Malibu Y. Cannabis use improves retention and
virological outcomes in patients treated for hepatitis C. Eur. J.
Gastroenterol. Hepatol. 2006;18(10):1057-1063.

Tomida I, Azuara-Blanco A, House H, Flint M, Pertwee RG, Robson PJ.
Effect of sublingual application of cannabinoids on intraocular
pressure:a pilot study. J. Glaucoma 2006;15(5):349-353.

Tseng AH, Harding JW, Craft RM. Pharmacokinetic factors in sex
differences in Delta 9-tetrahydrocannabinol-induced behavioral effects
in rats. Behav. Brain Res. 2004;154:77-83.

Verdejo-Garcia A, Lopez-Torrecillas F, Gimenez CO, Pérez-García M.
Clinical implications and methodological challenges in the study of the
neuropsychological correlates of cannabis, stimulant, and opioid abuse.
Neuropsychol. Rev.2004;14:1-41.

Wade DT, Makela P, Robson P, House H, Bateman C. Do cannabis-based
medicinal extracts have general or specific effects on symptoms in
multiple sclerosis? A double-blind, randomized, placebo-controlled study
on 160 patients. Mult. Scler. 2004;10(4):434-441.

Wade DT, Makela PM, House H, Bateman C, Robson P. Long-term use of a
cannabis-based medicine in the treatment of spasticity and other
symptoms in multiple sclerosis. Mult. Scler. 2006;12(5):639-645.

Wallace M, Schulteis G, Atkinson JH, Wolfson T, Lazzaretto D, Bentley H,
Gouaux B, Abramson I. Dose-dependent effects of smoked cannabis on
capsaicin-induced pain and hyperalgesia in healthy volunteers.
Anesthesiology 2007;107(5): 785-796.

Ware MA, Ducruet T, Robinson AR. Evaluation of herbal cannabis
characteristics by medical users: a randomized trial. Harm Reduct. J.
2006; 3:32. 

Wilsey B, Marcotte T, Tsodikov A, Millman J, Bentley H, Gouaux B,
Fishman S. A randomized, placebo-controlled, crossover trial of
cannabiscigarettes in neuropathic pain. J. Pain 2008; 9(6):506-521.

Wissel J, Haydn T, Müller J, Brenneis C, Berger T, Poewe W, Schelosky
LD. Low dose treatment with the synthetic cannabinoid Nabilone
significantly reduces spasticity-related pain: a doubleblind
placebo-controlled cross-over trial. J. Neurol. 2006;253(10):1337-1341.

Zajicek J, Fox P, Sanders H, Wright D, Vickery J, Nunn A, Thompson A; UK
MS Research Group. Cannabinoids for treatment of spasticity and other
symptoms related to multiple sclerosis (CAMS study): multicentre
randomised placebocontrolled trial. Lancet 2003;362(9395):1517-1526.

Zajicek JP, Sanders HP, Wright DE, Vickery PJ, Ingram WM, Reilly SM,
Nunn AJ, Teare LJ, Fox PJ, Thompson AJ. Cannabinoids in multiple
sclerosis (CAMS) study: safety and efficacy data for 12 months follow
up. J. Neurol. Neurosurg. Psychiatry 2005;76(12):1664-1669.

Zuardi AW, Shirakawa I, Finkelfarb E, Karniol IG. Action of cannabidiol
on the anxiety and other effects produced by delta-9-THC in normal
subjects. Psychopharmacology 1982;76:245-250.

Aanvullende publicaties:

Ben Amar M. Cannabinoids in medicine: A review of their therapeutic
potential. J. Ethnopharm. 2006;105:1-25.

Kogan NM, Mechoulam R. Cannabinoids in health and disease. Dialogues in
Clinical Neuroscience 2007;9 (no.4)

Grotenhermen F. Cannabinoids. Current Drug Targets – CNS &
Neurological Disorders, 2005, 4, 507-530.

Mechoulam R, Peters M, Murillo-Rodriguez E, Hanus LO. Cannabidiol –
Recent advances. Chemistry & Biodiversity 2007: Vol. 4

Elikottil J, Gupta P, Gupta K. The analgesic potential of cannabinoids.
Journal of Opioid Management 2009: 5:6

 PAGE    

 PAGE   5